Skip to content
Get BIO’s view on everything from health care to biofuels and the bioeconomy. The below articles include BIO statements, opinion, and calls to action, as well as articles and op-eds written by BIO leadership.
A year ago, the sentiment for the industry was extremely low. In 2023, the biotech stock indices were sliding to potential new lows, levels […]
5 reasons for investor optimism at BIO-Europe Spring 2024 Read More »
Editor’s Note: On Wednesday, May 1, 2024, the California Supreme Court said it will consider Gilead’s request for summary dismissal, agreeing with BIO’s March
BIO opposes lawsuit that would penalize drugmaker for innovating too slowly Read More »
The Inflation Reduction Act (IRA) is expected to have broad negative impacts on patients, most notably through less access to future cures and treatments.
Heart disease patients and the IRA’s misguided incentives Read More »
The COVID-19 pandemic laid bare the vulnerabilities of global supply chains, especially in the biopharmaceutical sector. “Nobody ever could have envisioned a global pandemic
Why building America’s biomanufacturing sector is critical for America’s security Read More »
Innovative companies using biotechnology to make renewable raw materials can enable more sustainable, climate-friendly manufacturing while providing an additional source of income for farmers.
BIO calls for legislation to boost biomanufacturing Read More »
President Biden delivered his third State of the Union address last night, March 7. Health care was a prominent theme throughout the night, which
Key takeaways from the State of the Union address Read More »
The World Trade Organization (WTO) 13th Ministerial concluded on Friday, March 1, without an agreement to expand the COVID-19 intellectual property waiver to therapeutics
WTO Ministerial ends, no expansion of COVID IP waiver Read More »
On Monday, March 4, the White House will host a “listening session” on the impact of Pharmacy Benefit Managers (PBMs). This is a welcome
As White House prepares ‘listening session’ on PBMs, here’s what they need to hear Read More »
Biotechnology Innovation Organization (BIO) member companies and CEOs sent a letter to congressional leaders urging them to pass the bipartisan ORPHAN Cures Act and
CEOs ask Congress to pass ORPHAN Cures Act Read More »
As the 13th Ministerial Conference of the World Trade Organization (WTO) kicks off (Feb. 26-29), the expansion of the COVID-19 IP waiver remains a
Why the WTO should focus on addressing trade-related aspects of pandemic preparedness Read More »
